Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. Juni 2018 08:00 ET | Quelle: Actinium Pharmaceuticals

Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial

Iomab-B remains the only targeted conditioning treatment in clinical trials with the potential to increase access to and improve outcomes of bone marrow transplant NEW YORK, June 26,...
18. April 2018 07:30 ET | Quelle: Actinium Pharmaceuticals

Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical Development

- Dr. Vijay Reddy joins Actinium with over 20 years of bone marrow transplant clinical experience including extensive product development experience at Pharmacyclics, an AbbVie Company, Medimmune and...
07. März 2018 07:30 ET | Quelle: Actinium Pharmaceuticals

Actinium Pharmaceuticals to Present at 30th Annual ROTH Conference

NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), announced today that it will be attending and presenting at the 30th...